Profile data is unavailable for this security.
About the company
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2016
- Employees220.00
- LocationI-MabSuite 400, 2440 Research BlvdROCKVILLE 20850United StatesUSA
- Phone+1 (301) 670-2800
- Websitehttps://www.i-mabbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 57.53m | 134.00 | 4.86 | 0.2302 | 1.76 | 0.2234 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 58.25m | 298.00 | -- | 1.33 | -- | 1.95 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 60.19m | 29.00 | -- | 0.9965 | -- | 6.23 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.80m | 25.00 | 20.58 | 5.51 | 19.94 | 5.43 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| Journey Medical Corp | 77.68m | 843.00k | 74.37m | 58.00 | 50.30 | 8.95 | 18.14 | 0.9574 | -0.0131 | -0.0131 | 3.91 | 0.5642 | 1.15 | 2.36 | 5.71 | 1,339,328.00 | 1.25 | -- | 5.17 | -- | 66.79 | -- | 1.09 | -- | 1.08 | 2.00 | 0.6682 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 74.41m | 43.00 | -- | 7.75 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 13.91m | -86.93m | 75.52m | 100.00 | -- | -- | -- | 5.43 | -1.88 | -1.88 | 0.3001 | -0.3133 | 0.2436 | -- | 2.68 | 139,080.00 | -152.23 | -55.75 | -196.62 | -78.33 | 84.02 | -- | -625.06 | -754.94 | 2.23 | -12.96 | 1.42 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 75.64m | 20.00 | -- | 7.70 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 85.38m | 165.00 | -- | -- | -- | 2.82 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 88.16m | 220.00 | -- | 0.3751 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 23.10m | -27.21m | 92.34m | 176.00 | -- | 10.24 | -- | 4.00 | -2.03 | -2.03 | 1.72 | 0.6731 | 0.3577 | 0.8917 | 2.39 | 131,250.00 | -41.56 | -34.75 | -62.38 | -46.91 | 56.81 | 55.98 | -116.17 | -153.72 | 2.36 | -- | 0.6718 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 94.37m | -4.77m | 119.44m | 237.00 | -- | 5.20 | -- | 1.27 | -0.169 | -0.169 | 3.21 | 0.7573 | 2.07 | 13.97 | 11.61 | 398,194.10 | -10.48 | -46.29 | -16.25 | -65.38 | 13.44 | 4.66 | -5.06 | -36.51 | 1.60 | -1.84 | 0.3144 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Assertio Holdings Inc | 132.19m | -345.11m | 123.94m | 53.00 | -- | 0.9378 | -- | 0.9376 | -4.11 | -4.11 | 1.44 | 1.39 | 0.3862 | 1.27 | 3.24 | 2,494,076.00 | -100.82 | -21.51 | -134.56 | -32.05 | 72.12 | 88.68 | -261.08 | -62.10 | 1.51 | -- | 0.2266 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
Data as of Sep 18 2024. Currency figures normalised to I-Mab's reporting currency: US Dollar USD
17.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 30 Jun 2024 | 6.91m | 8.54% |
| Caligan Partners LPas of 30 Jun 2024 | 3.37m | 4.17% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 1.38m | 1.71% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 576.60k | 0.71% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Jun 2024 | 566.65k | 0.70% |
| Two Sigma Investments LPas of 30 Jun 2024 | 478.44k | 0.59% |
| GSA Capital Partners LLPas of 30 Jun 2024 | 272.19k | 0.34% |
| Exome Asset Management LLCas of 30 Jun 2024 | 271.40k | 0.34% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 244.88k | 0.30% |
| Abaris Investment Management AGas of 31 Dec 2023 | 172.00k | 0.21% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
